aTyr Pharma, Inc.(US:ATYR) Globenewswire·2025-10-16 20:00Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the company announced disappointing clinical trial results [3][4]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about the drug's efficacy, particularly its ability to allow patients to taper steroid usage completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 16, 2025, to September 12, 2025, and shareholders are encouraged to register for potential lead plaintiff appointment [3][4]. - The deadline for shareholders to seek lead plaintiff status is December 8, 2025, and there is no cost or obligation to participate in the case [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].